Statements (26)
| Predicate | Object | 
|---|---|
| gptkbp:instanceOf | gptkb:antineoplastic_agent gptkb:drug | 
| gptkbp:administeredBy | intravenous infusion | 
| gptkbp:CASNumber | 158440-71-6 | 
| gptkbp:chemicalFormula | C15H14O6 | 
| gptkbp:clinicalTrialPhase | Phase II | 
| gptkbp:developedBy | gptkb:illudin_S | 
| gptkbp:discoveredBy | MGI Pharma | 
| gptkbp:legalStatus | gptkb:investigational_drug | 
| gptkbp:mechanismOfAction | gptkb:antineoplastic_agent induces DNA damage | 
| gptkbp:molecularWeight | 290.27 g/mol | 
| gptkbp:sideEffect | nausea vomiting fatigue myelosuppression | 
| gptkbp:synonym | 6-hydroxymethylacylfulvene MGI-114 hydroxymethylacylfulvene | 
| gptkbp:target | gptkb:cancer prostate cancer solid tumors | 
| gptkbp:usedFor | gptkb:cancer | 
| gptkbp:bfsParent | gptkb:illudin_S | 
| gptkbp:bfsLayer | 8 | 
| https://www.w3.org/2000/01/rdf-schema#label | irofulven |